Th1/Th2 ratio

The Th1/Th2 ratio is a pattern marker, not a pass/fail lab. It can be useful in narrow settings, especially recurrent pregnancy loss research and some inflammatory disease workups. It is not a routine screening test with a universal cutoff.

That matters because "Th1/Th2 ratio" is not one single assay. Some studies count Th1 and Th2 cells in peripheral blood. Others compare cytokines in serum, plasma, whole blood, or tumor tissue. Those are related clues, not the same measurement.

What This Number Measures

Helper T cells are CD4 white blood cells that coordinate immune responses. Th1 cells tend to drive cell-mediated inflammation against viruses, some bacteria, and tumor cells. Th2 cells help B cells make antibodies and are active in parasite defense and allergy. They can also quiet some Th1 signals.

Many research studies measure this with a venous blood draw and flow cytometry after the cells are stimulated. Flow cytometry is a lab method that tags cells and counts them one by one. A common version counts IFN-gamma-producing CD4 cells as Th1 and IL-4-producing CD4 cells as Th2.

Other studies use cytokine ratios, such as IFN-gamma to IL-4 or IFN-gamma to IL-10. Cytokines are short immune messages in blood. A cytokine ratio can point in the same direction as a cell-count ratio, but it cannot be compared as if it were the same test.

A higher ratio usually means Th1 activity is dominating. A lower ratio usually means Th2 activity is dominating. The hard part is interpretation: neither direction is good or bad by itself.

Pregnancy and Recurrent Miscarriage

Pregnancy needs immune tolerance. It does not turn inflammation off, but repeated unexplained miscarriages have been linked with stronger Th1 signals and weaker Th2 tolerance signals in peripheral blood studies.

A 2025 meta-analysis of flow-cytometry studies found a higher Th1(IFN-gamma)/Th2(IL-4) ratio in women with unexplained recurrent miscarriage than in fertile controls. That supports the biology. It does not make this a first-line miscarriage test.

Guidelines still do not recommend routine cytokine or immune testing for recurrent pregnancy loss. The reason is not that the biology is fake. The reason is that assays differ, cutoffs are not standardized, and treatment trials are still thin.

One open-label study selected women with recurrent pregnancy loss and an elevated flow-cytometry ratio. Cyclosporine lowered the Th1 tilt and raised the successful birth rate. Because the study was not randomized or blinded, treat it as suggestive rather than settled. It belongs in a reproductive immunology workup, not as a stand-alone answer.

Autoimmune and Inflammatory Disease

Autoimmunity is not just Th1. Some autoimmune diseases are driven more by antibodies, Th17 cells, or regulatory T-cell failure. Still, several active inflammatory conditions show a Th1-leaning pattern in blood.

In chronic immune thrombocytopenia, untreated patients had ratios about three times those of healthy controls, and treated groups were no longer clearly different from controls. In adult-onset Still's disease, peripheral blood ratios were higher during active disease and tracked with disease severity.

A meta-analysis in ankylosing spondylitis pooled 4,020 patients and 3,065 healthy controls and found higher Th1/Th2 ratios, especially in more active disease. Acute COPD flares also showed higher Th1/Th2 ratios than stable COPD. In hypothyroidism during early pregnancy, higher ratios traveled with different gut bacterial patterns, but that study was correlational.

Sepsis and Critical Illness

Sepsis is where one-way thinking fails. In one 117-person sepsis study using peripheral blood mononuclear cells, a higher Th1/Th2 ratio was tied to about twice the odds of dying within 28 days in the adjusted model.

A separate severe sepsis study measured Th2/Th1, the inverse ratio, in whole blood. Persistent Th2 dominance was tied to more ICU-acquired infections and higher 28-day mortality. Both studies point to the same lesson: in sepsis, either extreme can mark an immune system that is no longer responding well.

Cancer Prognosis

Cancer makes the simple story break. In gastric cancer, a peripheral blood IFN-gamma/IL-4 cell ratio before and after surgery separated groups with different five-year survival.

But a colorectal cancer study measured immune cells inside tumor tissue, not the blood ratio. In more than 2,000 patients, high densities of both Th1 and Th2 cells in tumors predicted better cancer-specific survival. That is a tumor-tissue finding, so it should not be read as a blood-test rule.

In liver cancer treated with transarterial chemoembolization, a shift toward Th1-type whole-blood cytokines after treatment was linked with longer survival. In melanoma treated with ipilimumab and interferon-alpha, higher peripheral Th1 cell profiles tracked with response, while higher Th2 profiles tracked with progression. The helpful direction depends on the cancer and the treatment.

The Brain and Nervous System

The nervous system data are interesting, but less mature. Parkinson's disease studies found a Th1-leaning blood profile in both drug-naive and treated patients. In moderate-to-severe Alzheimer's disease, a small uncontrolled supplement study found higher serum cytokine ratios at baseline and lower ratios after a year.

Temporal lobe epilepsy data mix human blood, human brain tissue, and rat experiments. In the human part, a higher peripheral Th1/Th2 ratio tracked with blood signs of nerve injury. In people at high risk for psychosis, one cytokine-balance study found that the Th2-dominant group was more likely to convert to psychosis over follow-up. These are research findings, not diagnostic uses.

Why Higher Is Not Better or Worse

This is not a good-number, bad-number marker. It is a pattern marker. A Th1 tilt can be a liability when your immune system is attacking your own tissue or threatening pregnancy tolerance. The same tilt can be useful when you need tumor control or intracellular infection control.

A Th2 tilt can be part of allergy and some poor sepsis patterns. It can also be part of tissue repair after stroke. So the ratio only makes sense against the condition, timing, assay method, and question being asked.

When Results Can Be Misleading

The biggest limitation is method mismatch. A cell-count ratio from stimulated whole blood, a serum cytokine ratio, and a tumor-tissue ratio should not be compared as if they were one number. Even within flow cytometry, stimulation method, gating, and sample handling can change the result.

• Different assay methods: labs may count Th1 and Th2 cells or measure cytokines. Use the same lab and method for trends.
• Acute infection, vaccination, or illness: these are meant to shift immune activity. A result drawn during or soon after one reflects that event.
• Recent surgery or anesthesia: surgery stress and anesthetic drugs can shift Th1/Th2 measures for days.
• Medications: corticosteroids suppress immune signaling, and some antidepressants may shift Th1/Th2 balance. The result must be read with your medication list.
• Sample handling: whole-blood flow assays can change if processing is delayed too long. Fast transport and consistent processing matter.
• Age and life stage: children, adults, pregnancy, and aging have different immune baselines. Your own same-method trend is usually more useful than someone else's number.

How To Use a Single Result

A single result is a prompt to look for context. First check what was measured: cells or cytokines, and in what specimen. Then read it beside symptoms and companion labs.

If the ratio is Th1-leaning, useful companions can include high-sensitivity CRP, a blood count, disease-specific autoimmune testing, and thyroid testing when pregnancy or thyroid symptoms are part of the story. If the result is Th2-leaning and you have allergic symptoms, IgE testing may be the more direct next step.

The ratio rarely changes a decision by itself. It earns its place when it points to the next better question.

Tracking Over Time

Trend this only when the method is the same each time. A change from one lab's cytokine ratio to another lab's flow-cytometry ratio is not a trend. It is a new test.

Because there is no universal cutoff, the most useful comparison is often your own baseline, measured under similar conditions and away from acute illness.